Eli Lilly Stock (LLY) Gains on Regulatory Win for Experimental Cancer Drug
Cancer treatments are a growth area for the drug company,
Eli Lilly & Co (LLY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 5,063,516 | $6,073,333,633 | +5% | 1.81% |
| 2. | 2,349,200 | $2,817,700,956 | +49% | 0.32% | |
| 3. | 1,881,500 | $2,256,727,545 | +10% | 0.26% | |
| 4. | AQR Capital Management Cliff Asness | 1,035,605 | $1,242,135,647 | +22% | 0.43% |
| 5. | Citadel Investment Group Ken Griffin | 945,456 | $1,134,008,290 | +292% | 0.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $691.79 | 715 | $494,626.99 | 14,685 | 2025-08-15 | Filing | |
| $660.25 | 758 | $500,472.53 | 758 | 2025-08-13 | Filing | |
| $647.36 | 1,000 | $647,360.00 | 20,562 | 2025-08-13 | Filing | |
| $644.77 | 1,632 | $1,052,263.01 | 546,601 | 2025-08-12 | Filing | |
| $634.41 | 1,000 | $634,405.00 | 137,660 | 2025-08-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1,175.10 | 6,500 | $7,638,150.00 | 54,147 | 2026-08-17 | Filing | |
| $1,185.01 | 2,000 | $2,370,020.00 | 1,526 | 2026-08-10 | Filing | |
| $1,190.00 | 5,000 | $5,950,000.00 | 11,875 | 2026-08-07 | Filing | |
| $1,150.77 | 2,500 | $2,876,925.00 | 29,804 | 2026-06-10 | Filing | |
| $996.18 | 2,208 | $2,199,572.06 | 91,881,150 | 2026-05-06 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 115,236 | $133,336,910 | 2.03% | |
| 2. | 26,968 | $31,204,133 | 2.2% | |
| 3. | 26,575 | $30,749,401 | 0.81% | |
| 4. | 21,162 | $24,486,127 | 17.47% | |
| 5. | 20,500 | $23,719,666 | 0.28% |
News See All
Biotech TRex Bio Set to Roar Onto Nasdaq With $133M IPO
Biotechnology group TRex Bio, backed by some of the biggest names in pharmaceuticals, is looking to raise as much as $133.3 million in a U.S. IPO. ...
10 Best Return on Equity (ROE) Stocks to Buy
High returns on equity can point to valuable businesses: payment networks that collect fees without funding consumer loans, software companies that sell the same product repeatedly, and semiconductor ...
Eli Lilly's Valuation Has Changed. Here's What Investors Need to Know
Eli Lilly and Company (NYSE:LLY) has carved out a strong position in the pharmaceutical industry, with much of its competitive advantage now tied to its leadership in diabetes and obesity treatments.
Eli Lilly (LLY) and AbbVie (ABBV) Are Expanding Their Pipelines. Their Valuations Tell Two Different Stories
Obesity drugs, pipeline investment, and manufacturing capacity are reshaping the pharmaceutical industry's growth equation.
Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics
Foghorn plans to layoff 40% of its staff.
Eli Lilly Stock (LLY) Moves Higher on Positive Trial Results for Zepbound Combo
The company has developed several medications for weight loss and diabetes.
Novo vs. Eli Lilly: Study Shows Ozempic Advantage over Mounjaro — Why This Matters for NVO Investors
Danish drug giant Novo ($NVO), in a Tuesday press statement, announced key findings from a real-world study that pitched its diabetes drug against ...
Novo Nordisk Just Beat Lilly in a Trial. Is the Comeback Finally Taking Shape?
Novo Nordisk (NYSE:NVO) finally has a CagriSema result it can put next to Eli Lilly's (NYSE:LLY) tirzepatide and come out ahead.
Can Roche’s Latest Obesity Drug Results Help it Challenge Eli Lilly and Novo Nordisk?
Roche's push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing...
Hedge Fund Resource Center